Press release from Companies
Published: 2024-10-04 15:50:51
On 3 October 2024, the exercise period for warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB’s ("PHI" or the "Company") rights issue of units in 2022 ("TO 4"), ended. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI is thus provided approximately SEK 5.2 million before deduction of transaction related costs.
During the exercise period, 12 september-3 October 2024, holders of TO 4 had the right to subscribe for one (1) new share in PHI at a subscription price of SEK 4.63 per share. In total, 1,129,513 warrants of series TO 4 were exercised, corresponding to a subscription rate of approximately 83.9 percent. PHI will thus receive approximately SEK 5.2 million before deduction of transaction related costs.
Conversion from interim shares to ordinary shares is expected to take place around 18 October 2024, and ordinary shares are expected to be visible on each subscriber's account approximately two banking days thereafter.
The exercise of TO 4 means that the number of shares in the Company increases by 1,129,513 shares and the share capital increases by SEK 225,902.60, resulting in a dilution effect of approximately 4.1 percent. When the new shares from TO 4 have been registered with the Swedish Companies Registration Office, the total number of shares in PHI will amount to 27,322,438 and the share capital will amount to SEK 5,464,487.60.
In connection with the warrant exercise, PHI has engaged Sedermera Corporate Finance AB as financial advisor, Foyen Advokatfirma i Sverige AB as legal advisor and Nordic Issuing AB as issuing agent.
For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
Web: www.sedermera.se
For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
